GILD

에 대한 최신 뉴스 Gilead Sciences (NASDAQ:GILD) 주식

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

IDXX

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Technicals

Signals

머크 앤드 컴퍼니(NYSE:MRK)와 길리어드 사이언스(NYSE:GILD)는 주가가 상당히 다른 양상을 보이는 두 제약 대기업이다. 뉴저지주 라웨이에 본사를 둔 머크는 방금 데스 크로스(Death Cross)를 표시하여 앞으로 발생할 수 있는 문제를 예고했다. 반면 캘리포니아주 포스터 시티에 본사를 둔 길리어드는 강세 모멘텀의 신호인 골든 크로스(Golden Cross)를 보여주고 있다.

머크의 데스 크로스 vs 길리어드의 골든 크로스: 서로 다른 양상을 보이는 두 제약 기업

Equities

Sector ETFs

Broad U.S. Equity ETFs

Markets

Tech

ETFs

BKNG

DXCM

GOOG

GOOGL

ISRG

LULU

MTTR

ODFL

ORLY

QCOM

TEAM

나스닥 100 지수는 목요일 또 다른 하락세를 보이며 변동성이 심한 세션 이후 6월 초 이후 최저 수준으로 마감했다. 전날 나스닥 100 지수는 3.7% 하락해 2022년 10월 이후 최악의 하락세를 기록했다.

나스닥 100 지수는 거의 2년 만에 최악의 2일 하락폭을 기록하며  7주 만에 최저치

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has risen 29.66% since its last report. The company recently reported that it has 23.41 million shares sold short, which is 1.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734636613_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(GILD) - Analyzing Gilead Sciences's Short Interest

—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026—
—Additional equity investment raises Gilead's ownership stake in Assembly Bio to 29.9%—
–Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio's novel small molecule hepatitis D virus candidate ABI-6250—
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced an equity investment of $20.1 million by Gilead Sciences, Inc. ("Gilead") to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%.
Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus (HDV) and hepatitis B virus (HBV). Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.
The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of HDV, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated.

Contracts

ASMB

Assembly Biosciences Announces $30.1M Equity Investment And Accelerated Funding From Gilead To Advance Clinical Development Programs; Additional Equity Investment Raises Gilead's Ownership Stake In Assembly Bio To 29.9%

Gilead Announces FDA Breakthrough Therapy Designation For Trodelvy For Second-Line Treatment Of Extensive-Stage Small Cell Lung Cancer

<ul>
<li>Gilead and Terray Will Leverage Terray's tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest.</li>
<li>Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration.</li>
<li>Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead.&nbsp;</li>
<li>If Gilead exercises its option to exclusively license the compounds directed to a target, Gilead will be responsible for further development and commercialization activities for products resulting from the collaboration. Terray will receive an upfront payment and is eligible to receive milestone payments associated with the achievement of preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration.</li>
</ul>

Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.26% on an annualized basis producing an average annual return of 12.66%. Currently, Gilead Sciences has a market capitalization of $114.05 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a price of $91.51 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734361210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

AMGN

EXEL

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

The final European Commission decision is anticipated in the first quarter of 2025. This follows the accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2024.
PBC is a rare, chronic, autoimmune disease of the bile ducts that affects approximately 15 per 100,000 people in Europe, primarily women, and can cause liver damage and possible liver failure if untreated. The most common symptoms of PBC are pruritus (chronic itch) and fatigue, which can be debilitating for some people. The disease currently has no cure and treatment goals for people living with PBC include suppressing liver damage and reducing the symptoms related to cholestasis. The effect of treatment on slowing disease progression is primarily measured by an improvement in liver biochemical tests, including the normalization of alkaline phosphatase (ALP) levels, an important marker of disease progression in PBC.

Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic acid (UDCA) In Adults With Inadequate Response To UDCA Alone, Or As Monotherapy In Those Unable To Tolerate UDCA

At the HIV Analyst &amp; Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed that it is developing a once-yearly injectable formulation for lenacapavir.
The annual formulation is currently in Phase 1 study, with data to be presented.
In its investor presentation, the company said it <a target="_blank" href="https://s29.q4cdn.com/585078350/files/doc_events/2024/Dec/10/GILD-HIV-Analyst-Investor-Event-Presentation-10-December-2024.pdf" rel="noreferrer noopener">expects</a> the pivotal Phase 3 pharmacokinetics study&#8217;s first patient to be in 2025, and potential regulatory filings will begin in late 2027.
In September, Gilead revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company&#8217;s twice-yearly injectable HIV-1&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">capsid inhibitor, lenacapavir</a>.
Lenacapavir reduced HIV infections by 96% compared to background HIV incidence.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook</a>
In November, the&nbsp;New England Journal of Medicine&nbsp;published the full results from Gilead&#8217;s Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for HIV prevention.
The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by 96% compared to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42225869/gilead-announces-new-england-journal-of-medicine-publication-of-purpose-2-results" rel="noreferrer noopener">background HIV incidence</a>.
Twice-yearly lenacapavir for PrEP also demonstrated superiority to once-daily Truvada&nbsp;(emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF) for PrEP and was generally well-tolerated, with no significant or new safety concerns identified.
In 2021, the FDA approved ViiV Healthcare&#8217;s Apretude, the first injectable form of PrEP administered every two months.
Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) own ViiV Healthcare.
STAT News <a target="_blank" href="https://www.statnews.com/2024/12/11/hiv-prevention-gilead-once-a-year-prep/?utm_campaign=rss" rel="noreferrer noopener">highlights</a> that Gilead plans to seek approval for a PrEP injection that requires only two clinic visits per year. This less frequent dosing has been shown to be more effective than traditional daily oral PrEP.
However, global access to these new PrEP options remains a challenge. Former CDC director Rochelle Walensky criticized ViiV for not prioritizing accessibility in Africa and urged Gilead to ensure broader availability <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash" rel="noreferrer noopener">of its drug lenacapavir</a>.
Unlike vaccines, which train the immune system to recognize and fight viruses long-term, PrEP relies on antivirals that are effective only while active in the body. The main challenge has been developing drugs that remain effective for extended periods.
While significant progress has been made with long-lasting PrEP, the same cannot be said for HIV vaccines.
Efforts to create a vaccine have struggled against the virus&#8217;s complexity, and no vaccines are currently in late-stage trials following recent setbacks.
The success of long-term PrEP may further complicate vaccine development by reducing the urgency for alternatives.
Price Action: GILD stock is up 0.73% at $93.05 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42467798/why-is-insurance-firm-centene-stock-trading-higher-on-thursday" target="_blank" rel="noreferrer noopener">Why Is Insurance Firm Centene Stock Trading Higher On Thursday?</a></li>
</ul>

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and maintains $80 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $80 Price Target

RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and maintains $84 price target.

RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target

In the preceding three months, 27 analysts have released ratings for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">13</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $96.0, along with a high estimate of $125.00 and a low estimate of $70.00. Observing a 14.82% increase, the current average has risen from the previous average price target of $83.61. 
<img src="https://www.benzinga.com/files/images/story/2024/1733839256_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Gilead Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$109.00</td>
<td>-</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$96.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$97.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gilead Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Gilead Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gilead Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Get to Know Gilead Sciences Better</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>A Deep Dive into Gilead Sciences's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 7.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Gilead Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 6.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.32%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.26, Gilead Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Gilead Sciences Stock

B of A Securities analyst Tim Anderson reinstates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Buy and announces $109 price target.

Initiation

B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $105 to $115.

Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $115

The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long-term survival. The data were shared in an oral presentation (Abstract #864) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
"There is growing evidence that people with follicular lymphoma and marginal zone lymphoma can experience long-term survival after one Yescarta treatment," said Dominique Tonelli, VP, Global Head of Medical Affairs, Kite. "With no lymphoma-specific events in the five-year follow-up of ZUMA-5 patients, Yescarta may offer patients the chance to live longer without need for subsequent therapy and a potential cure."

Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta

– Only CAR T to Demonstrate Prolonged Overall Survival After Five Years Follow-Up in Relapsed/Refractory Mantle Cell Lymphoma –
– ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients –
– Real-World Evidence Analysis Shows High Effectiveness and Safety Profile Consistent with ZUMA-3 in Broader Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Population –
Kite, a Gilead Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus&#xAE; (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
The data presented include an oral presentation (Abstract # 748) of a primary analysis of ZUMA-2 cohort 3 demonstrating an overall response rate (ORR) of 91% and complete response (CR) rate of 73% in Bruton tyrosine kinase inhibitor (BTKi)-naïve patients with R/R MCL. Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 (Abstract #4388), showed that 39% of patients with R/R MCL were still alive after five years, underscoring Tecartus as the only CAR T to have five-year follow-up data in this patient population. In addition, real-world evidence outcomes in adults with R/R B-ALL treated with Tecartus (Abstract # 5092 and #4193) demonstrated a high effectiveness and consistent safety profile in a broader patient population than the pivotal ZUMA-3 study.

Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients

On Sunday, Arcellx, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42382314/arcellx-announces-new-positive-data-for-its-immagine-1-study-in-patients-with-relapsed-or-refracto" rel="noreferrer noopener">multiple myeloma (RRMM)</a>.
The data will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. Anito-cel is partnered with Kite, a Gilead Science Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) company.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37544416/arcellxs-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson-johnson" rel="noreferrer noopener">Arcellx&#8217;s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson &amp; Johnson&#8217;s Multiple Myeloma Cell Therapies: Morgan Stanley</a>
The Phase 2 iMMagine-1 data are from an October 31 data cutoff date, with a median follow-up of 9.5 months for the efficacy evaluable population.
At the time of the data cut, 86 patients were evaluable for efficacy based on a follow-up of at least two months after treatment with anito-cel, and 98 patients were evaluable for safety based on a follow-up of at least one month after treatment with anito-cel.
Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a high-risk fourth-line or higher RRMM population, including triple- and penta-class refractory disease.
The overall response rate (ORR) was 97% (83/86), with a complete response/stringent complete response (CR/sCR) rate of 62% (53/86) and a very good partial response or higher (&gt;VGPR) rate of 81% (70/86).
Of those evaluable for minimal residual disease (MRD) testing, 93.1% (54/58) achieved MRD negativity at a minimum of 10-5&nbsp;sensitivity.
Median progression-free survival (mPFS) and overall survival (OS) were not reached, with 6-month PFS and OS rates being 93.3% and 96.5%, respectively, and 12-month PFS and OS rates being 78.5% and 96.5%, respectively.
No delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, have been observed to date in more than 150 patients dosed with anito-cel.&nbsp;
Price Action: ACLX stock is up 6.46% at $90.01 during the premarket session at last check Monday.
Photo via Shutterstock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42371469/blue-shields-500-million-drug-savings-initiative-with-amazon-pharmacy-can-potentially-launch-in-january" target="_blank" rel="noreferrer noopener">Blue Shield&#8217;s $500 Million Drug Savings Initiative With Amazon Pharmacy Can Potentially Launch In January</a></li>
</ul>

Movers

ACLX

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

– Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) –
– RWE Shows Decreasing Trend Over Time of Cytokine Release Syndrome and Related Adverse Events After Yescarta Treatment in Third-Line Plus Setting –
– Findings from ALYCANTE Study Show Stable Long-Term Quality of Life for R/R LBCL Patients Treated with Yescarta –

Reported Sunday, Gilead's Kite Highlights New Data Showcasing Yescarta's Curative Potential In Relapsed/Refractory Large B-Cell Lymphoma At ASH 2024

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $103,960, and 7, calls, for a total amount of $499,525.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $97.5 for Gilead Sciences over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale activity within a strike price range from $75.0 to $97.5 in the last 30 days. 
<h3>Gilead Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733256943_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.65</td>
<td>$2.5</td>
<td>$2.61</td>
<td>$95.00</td>
<td>$236.6K</td>
<td>11.5K</td>
<td align="right">920</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.3</td>
<td>$2.21</td>
<td>$2.3</td>
<td>$94.00</td>
<td>$103.9K</td>
<td>1.2K</td>
<td align="right">883</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.91</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$94.00</td>
<td>$90.2K</td>
<td>622</td>
<td align="right">493</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$90.00</td>
<td>$52.5K</td>
<td>936</td>
<td align="right">76</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.25</td>
<td>$19.25</td>
<td>$19.25</td>
<td>$75.00</td>
<td>$38.5K</td>
<td>3.2K</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Where Is Gilead Sciences Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,570,655, the GILD's price is down by -0.41%, now at $93.63. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 63 days.</li>
</ul>
<h3>Expert Opinions on Gilead Sciences</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $97.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Gilead Sciences, targeting a price of $105. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Gilead Sciences, targeting a price of $96. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Gilead Sciences, maintaining a target price of $105. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Gilead Sciences, which currently sits at a price target of $84. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Gilead Sciences, which currently sits at a price target of $95. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At Gilead Sciences's Recent Unusual Options Activity

The biotech sector's AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on... The biotech sector is poised for a significant boom in 2025, driven by innovative adaptive trial designs that cut time and costs while enhancing drug efficacy predictions. This favorable landscape presents an opportunity for investors to explore fundamentally strong biotech stocks with promising pipelines: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>).
The biotech sector is revolutionizing healthcare by targeting new and rare diseases with cutting-edge vaccines and therapies, driven by the rising demand for personalized medicine. Regulatory agencies like the FDA and EMA are streamlining processes to match technological advancements, propelling the global biotechnology market toward a projected $3.88 trillion by 2030, with an impressive <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Notably, AI and machine learning are transforming drug discovery by optimizing molecule screening and improving clinical outcome analysis. Beyond oncology and neurology, AI is driving advancements across diverse therapeutic areas. Deloitte estimates that biopharma companies investing in AI over the next five years could see up to an <a href="https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html">11% increase</a> in value relative to revenue across various functional areas.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 20.6% returns over the past year. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, VRTX's 39.89% is considerably higher than the 2.49% industry average. Likewise, its 28.83% trailing-12-month levered FCF margin is significantly higher than the 2.32% industry average. Furthermore, its 0.48x trailing-12-month asset turnover ratio is 17.3% higher than the 0.41x industry average.
VRTX's net revenues for the third quarter, which ended on September 30, 2024, increased 11.6% year-over-year to $2.77 billion. Its non-GAAP net income stood at $1.05 billion, or $4.01 per share, up 7.5% and 7.4%, respectively, compared to the prior-year quarter. Furthermore, its non-GAAP operating income rose 11.4% year-over-year to $1.31 billion.
Street expects VRTX's revenue for the quarter ending December 31, 2024, to increase 10.5% year-over-year to $2.78 billion. Its EPS for fiscal 2025 is expected to grow considerably year-over-year to $18.79. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, VRTX's stock has gained 30.4% to close the last trading session at $464.50.
VRTX's positive outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Value, Stability, and Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #21 out of 335 stocks in the Biotech industry. Beyond what we stated above, we also have given VRTX grades for Growth, Momentum, and Quality. Get all the VRTX ratings <a href="https://stocknews.com/stock/VRTX/">here</a>.
Stock #2: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its product portfolio includes Enbrel, Neulasta, Prolia, and Xgeva.
On September 24, 2024, AMGN announced that TEPEZZA (Teprotumumab) has been approved in Japan for treating active Thyroid Eye Disease (TED), making it the first and only approved treatment in the country. The approval is based on positive Phase 3 trial results, with additional trials ongoing for chronic TED patients.
AMGN's trailing-12-month gross profit margin of 60.59% is 4.1% higher than the industry average of 58.20%. Likewise, its trailing-12-month EBIT margin and levered FCF margin of 20.51% and 14.06% are 723.3% and 505.5% higher than the industry averages of 2.49% and 2.32%, respectively.
During the fiscal third quarter, which ended on September 30, 2024, AMGN's total revenues and non-GAAP operating income increased by 23.2% and 18.8% year-over-year, reaching $8.50 billion and $4.04 billion, respectively. Moreover, its non-GAAP net income grew 13.4% compared to the previous year, reaching $3.02 billion. Also, its non-GAAP net income per share grew 12.5% from the year-ago value to $5.58.
Analysts expect AMGN's revenue for the quarter ending December 31, 2024, to increase 8.1% year-over-year to $8.86 billion. Its EPS for the same quarter is expected to grow 7.1% year-over-year to $5.04. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained marginally closing the last trading session at $274.78.
AMGN's POWR Ratings reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system.
AMGN has a B grade for Growth and Quality. Within the same industry, it is ranked #17. <a href="https://stocknews.com/stock/AMGN/">Click here</a> for the additional POWR Ratings of AMGN (Value, Momentum, Stability, and Sentiment).
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
On December 3, 2024, GILD and Tubulis announced an exclusive option and license agreement to develop an antibody-drug conjugate (ADC) for a solid tumor target. The collaboration leverages Tubulis' advanced ADC platforms and GILD's oncology expertise to address challenges like durability and off-target toxicity.
On September 10, 2024, GILD and Genesis Therapeutics announced a collaboration to use Genesis' GEMS AI platform to discover and optimize small molecule therapies for selected targets. GILD gains exclusive rights to develop and commercialize the resulting compounds.
In terms of the trailing-12-month EBITDA margin, GILD's 49.29% is 763.7% higher than the 5.71% industry average. Likewise, its 77.80% trailing-12-month gross profit margin is 33.7% higher than the 58.20% industry average. Its 0.48x trailing-12-month asset turnover ratio is 17.5% higher than the 0.41x industry average.
In the fiscal third quarter, which ended on September 30, 2024, GILD's total revenues increased 7% year-over-year to $7.55 billion. The company's non-GAAP operating income was $3.26 billion, up 1.1% from the previous year's quarter. Additionally, its non-GAAP net income attributable to GILD stood at $2.53 billion, or $2.02 per share.
For the quarter ending December 31, 2024, GILD's revenue is expected to increase marginally year-over-year to $7.15 billion. Its EPS for fiscal 2025 is expected to grow 71.4% year-over-year to $7.56. GILD surpassed the EPS estimates in three of the trailing four quarters. Over the past six months, the stock has gained 41.4% to close the last trading session at $91.77.
It's no surprise that GILD has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It is ranked first in the Biotech industry. It has an A grade for Value and a B for Growth, Sentiment, and Quality. <a href="https://stocknews.com/stock/GILD/">Click here</a> to see GILD's Momentum and Stability ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $273.03 per share on Thursday afternoon, down $0.38 (-0.14%). Year-to-date, AMGN has declined -2.34%, versus a 28.52% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/amgn-vrtx-gild-3-biotech-stocks-with-promising-pipelines/>3 Biotech Stocks With Promising Pipelines</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks With Promising Pipelines

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the field. Given the robust prospect, investors looking for fundamentally sound biotech stocks might consider adding Regeneron Pharmaceuticals (REGN), Amgen (AMGN), and Gilead Sciences (GILD) to their portfolio. Read on… Thanks to groundbreaking advancements in precision medicine and immunotherapy, the biotech industry is undergoing a transformative phase, particularly in cancer treatment. The companies are reshaping the way cancer is diagnosed and treated with innovations.
Below, I have highlighted three fundamentally strong biotech stocks: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), which are well-positioned for long-term growth with their research breakthroughs.
Immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors, has been a <a href="https://www.yalemedicine.org/news/how-immunotherapy-can-treat-cancer-and-autoimmune-diseases">game-changer for cancer treatment</a>. These approaches enable the immune system to recognize and attack cancer cells more effectively. Companies pioneering such therapies are seeing robust growth, driven by the high efficacy and increasing adoption of their treatments.
With the global cancer burden increasing, the demand for innovative treatments is also surging. In the third quarter of 2024, the US Food and Drug Administration (FDA) <a href="https://www.aacr.org/blog/2024/10/03/fda-approvals-in-oncology-july-september-2024/">approved 16 oncology drugs</a>, including six new agents and 25 expanded indications for existing drugs.
The global biotechnology market is anticipated to <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reach $3.88 trillion by 2030</a>, exhibiting a CAGR of 13.9%. The market is driven by strong government support, improvement in approval processes, and standardization of clinical studies. Companies with strong pipelines and innovative therapies stand to gain as these treatments revolutionize the healthcare landscape.
With that in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, starting with the third choice.
Stock #3: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.  The company's products include EYLEA injection, Dupixent Injection, Libtayo Injection, Praluent Injection, Kevzara Injection, and others.
On December 9, REGN announced new and positive data for odronextamab monotherapy in patients with previously untreated follicular lymphoma with twelve abstracts spanning several B-cell non-Hodgkin lymphoma (B-NHL) subtypes. It demonstrates the effectiveness of the paradigm-changing potential of the odronextamab development program.
As per Elizabeth Brém, Associate Clinical Professor, Division of Hematology/Oncology at UC Irvine, "The OLYMPIA-1 Phase 3 trial is designed to explore a novel, chemotherapy-free, fixed duration treatment that is being studied in the outpatient setting in patients with previously untreated follicular lymphoma."
On November 6, REGN received approval from the European Commission for Dupixent&#xAE; (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1 to 11 years. This approval expands EoE in adults and adolescents, creating a milestone in treating pediatric patients. 
REGN, for the third quarter (ended September 30, 2024), reported total revenues of $3.72 billion, indicating a 10.6% growth from the prior-year quarter. Its income from operations increased 6.2% year-over-year to $1.18 billion. The company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $1.46 billion and $12.46 per share, up 10% and 7.5% year-over-year, respectively.
The consensus revenue estimate of $3.63 billion for the fiscal first quarter (ending March 2025) represents a 15.4% increase year-over-year. The consensus EPS estimate of $10.95 for the same quarter indicates a 14.6% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
The stock has gained marginally intraday to close the last trading session at $788.
REGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
REGN has a B grade for Value and Quality. It is ranked #27 out of 332 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/REGN/">Click here</a> to see the additional ratings for REGN (Growth, Momentum, Stability, and Sentiment).
Stock #2: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics globally. The company's product portfolio includes Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA.
On December 7, AMGN announced new data that demonstrates adding BLINCYTO&#xAE; (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones.
The same week, AMGN announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This expansion will help AMGN to meet the growing demand for therapies and enhance the company's global biomanufacturing network.
For the third quarter of 2024, which ended on September 30, AMGN's total revenues increased 23.2% year-over-year, amounting to $8.50 billion. The company reported non-GAAP income from operations of $4.04 billion, indicating an 18.8% increase from the prior-year quarter.
In addition, AMGN's non-GAAP net income came in at $3.02 billion, up 13.4% year-over-year, while its non-GAAP net income per share grew 12.5% from the year-ago value to $5.58. Its adjusted free cash flow rose 31.9% from the year-ago value to $3.31 billion.
As per the updated financial guidance for the full year 2024, AMGN now forecasts revenue to be in the range of $33 billion to $33.80 billion and its non-GAAP EPS between $19.20 and $20.
Street expects AMGN's revenue for the fiscal fourth quarter (ending December 2024) to increase 8% year-over-year to $8.85 billion. Its EPS for the same period is expected to register a 6.8% growth from the prior year, settling at $5.03. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters, which is promising.
AMGN's stock has surged 3.2% over the past year to close the last trading session at $277.63.
AMGN's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth and Quality. Within the same industry, it is ranked #18 out of 332 stocks. <a href="https://stocknews.com/stock/AMGN/">Click here</a> to see AMGN's ratings for Value, Momentum, Stability, and Sentiment.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company dedicated to advancing treatments for life-threatening diseases such as human immunodeficiency virus (HIV), viral hepatitis, COVID-19, and cancer.  Its portfolio of marketed products includes Biktarvy, Genvoya, Odefsey, Truvada, Harvoni, Vemlidy, and Veklury, among others.
On December 9, GILD announced positive results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas including follicular lymphoma or marginal zone lymphoma. Dr. Sattva S. Neelapu, lead investigator at the University of Texas MD Anderson Cancer Center, believes that such impressive results may have a curative effect on difficult-to-treat blood cancers.
In the same month, GILD and Tubulis entered an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. Under this agreement, GILD will gain access to Tubulis' proprietary Tubutecan and Alco5 platforms, and Tubulis will receive a payment of $20 million. This agreement will allow GILD to explore a range of solutions to help increase the therapeutic value of the ADC modality.
In the fiscal second quarter, which ended on June 30, 2024, GILD's total revenues increased 5.4% year-over-year to $6.95 billion. The company reported operating income of $2.64 billion, indicating 58.8% growth from the prior-year quarter. GILD's non-GAAP net income attributable came in at $2.52 billion, up 49.2% year-over-year, while its non-GAAP EPS grew 50% from the year-ago value to $2.01.
According to the full-year guidance, GILD forecasts product sales to range from $27.10 billion to $27.50 billion. The company also expects non-GAAP EPS to be between $3.60 and $3.90, an increase from the previous guidance of $6.85 to $7.25.
Analysts expect GILD's revenue and EPS for the current year (ending December 2024) to be $28.30 billion and $4.42, respectively. For the fiscal year 2025, its revenue and EPS are expected to grow marginally, and 69.8% from the prior year to $28.31 billion and $7.50, respectively.
Over the past six months, the stock has gained 40%, closing the last trading session at $90.59.
GILD's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and Sentiment and a B for Growth and Quality. The stock is ranked first in the Biotech industry. <a href="https://stocknews.com/stock/GILD/">Click here</a> to access the additional GILD ratings (Momentum and Stability).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $276.77 per share on Tuesday afternoon, down $0.86 (-0.31%). Year-to-date, AMGN has declined -1.00%, versus a 28.22% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/amgn-gild-regn-3-biotech-stocks-revolutionizing-cancer-treatment/>3 Biotech Stocks Revolutionizing Cancer Treatment</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Revolutionizing Cancer Treatment

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys

Oppenheimer previewed the upcoming year for the firm's Biotechnology coverage and said the firm's top ideas for 2025 are Capricor (CAPR), Gilead (G...

Capricor, Gilead, Kymera, Praxis among Oppenheimer's top biotech picks for 2025

Assembly Biosciences (ASMB) announced an equity investment of $20.1M by Gilead Sciences (GILD) to purchase additional Assembly Bio common stock and...

Assembly Biosciences announces $30.1M investment, funding from Gilead

Gilead raises Assembly Bio stake to ~30%

Impax US Sustainable Economy Fund Q3 2024 Commentary

Dividend Champion, Contender, And Challenger Highlights: Week Of December 22

SA Asks: Which Big Pharmas are likely to announce big M&A deals?

AAPL

AGNC

ALIZF

ALRS

AMAT

APLE

ARCC

AVGO

BABA

BASFY

BAYZF

BCPC

BIIB

BXSL

CAPR

CBAUF

CBRE

CRSP

CSCO

CSWC

CUBE

CZFS

FFMR

FMAO

FSNUF

FULT

GAIN

GLAD

GNTY

GOOD

GSBD

GWRS

HASI

HLAN

HOFT

HTGC

HUBS

INDB

INTC

INVH

KYMR

MAIN

MFIC

MLTX

MRNA

MSFT

NEWT

NRIM

NVDA

NWFL

OBDC

PINS

PRAX

PRTA

RITM

SEIC

SEMHF

SFBS

SHEL

SPTN

STAG

STWD

SWKS

THFF

TROW

TRUX

UNIT

VRTX

XRAY

Press Releases

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Comments

Gilead Sciences

뉴스

에 대한 최신 뉴스 Gilead Sciences (NASDAQ:GILD) 주식

월요일, 12월 23, 2024

화요일, 9월 03, 2024

목요일, 7월 25, 2024

일요일, 6월 23, 2024

토요일, 6월 22, 2024

화요일, 4월 09, 2024

월요일, 4월 01, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌